Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combizym + bifidobacterium
- Development stage
- Unknown
- Lead developer
- Nordmark Pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Combizym + bifidobacterium is a combination product consisting of digestive enzymes (as found in the branded product Combizym) and probiotic bacteria from the genus Bifidobacterium. Combizym contains pancreatin (lipase, protease, amylase) and additional fungal-derived enzymes (cellulase, protease, amylase from Aspergillus oryzae), used to aid digestion in cases of enzyme deficiency or digestive disorders[7]. Bifidobacterium is a probiotic microorganism that helps restore intestinal flora balance and may prevent gastrointestinal disturbances such as post-antibiotic diarrhea[4]. The combination aims to support both enzymatic digestion and gut microbiota health. Clinical studies have evaluated this combination for prevention of colon polyp recurrence and for improving dyspepsia symptoms[1][5].
02
Targets
CTRC (Chymotrypsin C)PNLIP (Pancreatic triacylglycerol lipase)PRSS1 (Trypsin family)AMY (Pancreatic alpha-amylase)
Beyond the preview
Go deeper on Combizym + bifidobacterium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Combizym + bifidobacterium.